GLP1 Agonists, the Promise of SELECT and Implications for Diabetes Drugs in PCI Patients
Presenter:
We Recommend
Disclosures
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
- Grant Support/Research Contract - Abbott
- Consultant Fee/Honoraria/Speaker's Bureau - Amgen; AstraZenca; Bard Medical; Biotronik; Boehringer Ingelheim; Boston Scientific Corporation; Daiichi-Sankyo/Elil Lilly and Company; Medtronic; Pfizer; Terumo Medical Corporation; Abbott